Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 5/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | SMC2 | O95347 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.30 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615255 | 0.81 | NR3C1 (0.33) | NR3C1KDM4CPDE4APDE4BPDE4C | |
| SCHEMBL31107272 | 0.72 | DPP4 (0.39) | KDM4CKDM2B | |
| SCHEMBL24558219 | 0.72 | HTT (0.33) | NR3C1 | |
| SCHEMBL24558204 | 0.69 | ADORA2A (0.32) | — | |
| SCHEMBL1343248 | 0.66 | CDK1 (0.42) | NR3C1KDM4CKDM2B | |
| SCHEMBL4323205 | 0.66 | MAPK14 (0.37) | KDM4CKDM2BPDE4APDE4BPDE4C | |
| SCHEMBL616982 | 0.65 | MAP2K2 (0.37) | CSNK2A2KDM4CKDM2BEGLN1SMC2 | |
| SCHEMBL21068031 | 0.64 | CSNK2A1 (0.52) | CSNK2A2CSNK2A1CSNK2BCSNK2A3 | |
| SCHEMBL11633469 | 0.64 | CDK1 (0.43) | NR3C1 | |
| SCHEMBL10290716 | 0.63 | CDK1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | CSNK2A2 865/4885CSNK2A1 902/4885NR3C1 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.